Shanghai Nuotie Asset Management Co., Ltd. signed the share transfer agreement to acquire 5.07% stake in Zhejiang Garden Bio-chemical High-tech Co., Ltd. from Zhejiang Xiangyun Technology Co., Ltd. for approximately CNY 370 million.
January 17, 2021
Share
Shanghai Nuotie Asset Management Co., Ltd. signed the share transfer agreement to acquire 5.07% stake in Zhejiang Garden Bio-chemical High-tech Co., Ltd. (SZSE:300401) from Zhejiang Xiangyun Technology Co., Ltd. for approximately CNY 370 million on January 18, 2021. Under the agreement, Zhejiang Xiangyun Technology Co., Ltd. will transfer 27,550,500 shares in Zhejiang Garden Bio-chemical High-tech Co., Ltd. at a price of CNY 13.35 per share.
Zhejiang Garden Biopharmaceutical Co Ltd, formerly Zhejiang Garden Bio-chemical High-tech Co Ltd, is a China-based company mainly engaged in the research, development, production and sales of vitamin D3 upstream and downstream products. The Company's vitamin products mainly include lanolin cholesterol, food and pharmaceutical grade vitamin D3, 25-hydroxyvitamin D3 and others. The Company also focuses on the research and development, production and sales of high-tech barrier preparations in the fields of cardiovascular, nervous system and other chronic diseases. The other products of the Company include Levofloxacin Tablets, Doxofylline Injection, Lipoic Acid Injection, Escitalopram Oxalate Tablets and others.
Shanghai Nuotie Asset Management Co., Ltd. signed the share transfer agreement to acquire 5.07% stake in Zhejiang Garden Bio-chemical High-tech Co., Ltd. from Zhejiang Xiangyun Technology Co., Ltd. for approximately CNY 370 million.
ZHEJIANG GARDEN BIOPHARMACEUTICAL CO.,LTD. 
